PPAR𝜹 Agonist GW501516 Inhibits PDGF-Stimulated Pulmonary Arterial Smooth Muscle Cell Function Related to Pathological Vascular Remodeling

Figure 2

PDGF upregulates PPARδ expression in a time- and dose-dependent manner. HPASMCs were made quiescent for 24 h and then treated with PDGF with increasing concentrations of PDGF for 24 h to study the effect of dose (a, b) or treated with PDGF (10 ng/mL) to study the effect of time, as indicated (c, d). The results were quantified by densitometry and normalized with respect to β-action; the control was set to 1.0. Results are expressed as the means ± SD of at least three independent experiments. ^∗𝑃<0.01 versus control nontreated cells; ^†𝑃<0.05 versus control nontreated cells.

(a)

(b)

(c)

(d)